EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, JW (Cayman) Therapeutics Co's enterprise value is $41.33 Mil.
JW (Cayman) Therapeutics Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-109.82 Mil. Therefore, JW (Cayman) Therapeutics Co's EV-to-EBITDA for today is -0.38.
The historical rank and industry rank for JW (Cayman) Therapeutics Co's EV-to-EBITDA or its related term are showing as below:
JWCTF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.13 Med: -0.1 Max: 1.17
Current: -0.38
During the past 6 years, the highest EV-to-EBITDA of JW (Cayman) Therapeutics Co was 1.17. The lowest was -4.13. And the median was -0.10.
JWCTF's EV-to-EBITDA is ranked worse than 100% of 455
companies
in the Biotechnology industry
Industry Median: 10.21
vs JWCTF: -0.38
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of JW (Cayman) Therapeutics Co's EV-to-EBITDA
For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JW (Cayman) Therapeutics Co's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where JW (Cayman) Therapeutics Co's EV-to-EBITDA falls into.
JW (Cayman) Therapeutics Co EV-to-EBITDA Calculation
JW (Cayman) Therapeutics Co's current Enterprise Value is $41.33 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. JW (Cayman) Therapeutics Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-109.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JW (Cayman) Therapeutics Co (OTCPK:JWCTF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
JW (Cayman) Therapeutics Co's PE Ratio for today is calculated as:
JW (Cayman) Therapeutics Co's share price for today is $0.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. JW (Cayman) Therapeutics Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.262.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
JW (Cayman) Therapeutics Co EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Business Description
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
JWCTF has been successfully added to your 